Artivion (NYSE:AORT) Price Target Raised to $46.00 at Stifel Nicolaus

Key Points

• Artivion's price target has been increased by Stifel Nicolaus from $40.00 to $46.00, reflecting a potential upside of 10.58% from its previous close.
• Multiple analysts have rated Artivion as a "buy," with an average price target of $43.13 and one analyst having a "Strong Buy" rating.
• Artivion reported a quarterly earnings per share of $0.24, exceeding expectations and showing a 15.3% year-over-year revenue increase.

Artivion (NYSE:AORT - Get Free Report) had its price target increased by equities research analysts at Stifel Nicolaus from $40.00 to $46.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Stifel Nicolaus' price objective points to a potential upside of 10.58% from the stock's previous close.

Several other equities analysts have also weighed in on the company. JMP Securities lifted their price target on Artivion from $33.00 to $42.00 and gave the company a "market outperform" rating in a research note on Friday, August 8th. Canaccord Genuity Group upped their price objective on Artivion from $41.00 to $50.00 and gave the company a "buy" rating in a report on Monday. LADENBURG THALM/SH SH lowered Artivion from a "buy" rating to a "neutral" rating and boosted their target price for the company from $32.00 to $38.80 in a research report on Wednesday, August 13th. Needham & Company LLC upped their price objective on Artivion from $45.00 to $50.00 and gave the stock a "buy" rating in a research report on Friday, August 22nd. Finally, Oppenheimer reaffirmed an "outperform" rating on shares of Artivion in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, Artivion presently has an average rating of "Buy" and an average price target of $43.13.

Artivion Price Performance

Artivion stock traded up $0.54 during midday trading on Monday, reaching $41.60. 76,773 shares of the stock traded hands, compared to its average volume of 444,783. The stock has a market cap of $1.96 billion, a P/E ratio of -99.04 and a beta of 1.70. Artivion has a 12 month low of $21.97 and a 12 month high of $45.07. The stock's fifty day moving average is $39.32 and its 200-day moving average is $31.47. The company has a quick ratio of 3.48, a current ratio of 4.78 and a debt-to-equity ratio of 0.52.

Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.13. The firm had revenue of $112.97 million for the quarter, compared to the consensus estimate of $107.96 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.Artivion's revenue was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Artivion will post 0.37 EPS for the current year.

Insider Activity at Artivion

In other Artivion news, SVP Jean F. Holloway sold 10,000 shares of the business's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $44.37, for a total value of $443,700.00. Following the transaction, the senior vice president directly owned 172,129 shares in the company, valued at $7,637,363.73. The trade was a 5.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Marshall S. Stanton sold 18,200 shares of the business's stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $44.02, for a total transaction of $801,164.00. Following the sale, the senior vice president directly owned 64,200 shares of the company's stock, valued at approximately $2,826,084. This trade represents a 22.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 74,858 shares of company stock worth $3,250,129 in the last quarter. 7.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Artivion

A number of large investors have recently bought and sold shares of the company. Franklin Resources Inc. boosted its position in shares of Artivion by 1.9% in the 2nd quarter. Franklin Resources Inc. now owns 29,263 shares of the company's stock valued at $910,000 after purchasing an additional 533 shares during the period. Smartleaf Asset Management LLC increased its position in shares of Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock worth $52,000 after acquiring an additional 538 shares during the last quarter. Illinois Municipal Retirement Fund grew its holdings in shares of Artivion by 3.1% during the first quarter. Illinois Municipal Retirement Fund now owns 20,519 shares of the company's stock valued at $504,000 after purchasing an additional 611 shares during the last quarter. MCF Advisors LLC lifted its position in Artivion by 109.3% in the first quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock worth $29,000 after purchasing an additional 614 shares during the period. Finally, Creative Planning raised its stake in Artivion by 5.6% during the 2nd quarter. Creative Planning now owns 14,272 shares of the company's stock valued at $444,000 after purchasing an additional 753 shares during the period. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.